BACKGROUND AND OBJECTIVES: Long pentraxin 3 (PTX3) is a multimeric inflammatory mediator. Increased serum PTX3 levels have been reported among end-stage renal disease patients. Moreover, PTX3 has been suggested to represent a novel mortality risk factor, and elevated PTX3 levels have been shown to accompany increased albuminuria among patients with chronic kidney disease (CKD). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We analyzed data of 49 persons with stage 1 diabetic CKD and 32 healthy subjects in a prospective controlled trial. Endothelial dysfunction was determined by flow-mediated dilation (FMD). Serum PTX3, high-sensitivity C-reactive protein (hs-CRP) levels, and FMD were studied in baseline and after 12 wk of ramipril therapy. Stepwise multivariate regression analysis evaluated the association of FMD with clinical and serologic parameters. RESULTS: Serum PTX3, hsCRP, and albumin levels and proteinuria were significantly decreased, and FMD levels were significantly increased, after ramipril treatment. FMD was negatively correlated with serum PTX3, 24-h proteinuria, and hsCRP levels and positively correlated to serum albumin both at baseline and after the 12-wk treatment period. Multivariate regression analysis revealed that PTX3 levels were independently related to FMD both before and after ramipril treatment. CONCLUSIONS: Our study shows that serum PTX3 levels are associated with endothelial dysfunction in patients with stage 1 diabetic CKD, independent of CRP. In addition, short-term ACE-inhibitor treatment significantly improves FMD and normalizes PTX3, hsCRP, and urinary protein excretion. (NCT: The study was registered in clinicaltrials.gov as NCT00674596.).
BACKGROUND AND OBJECTIVES: Long pentraxin 3 (PTX3) is a multimeric inflammatory mediator. Increased serum PTX3 levels have been reported among end-stage renal diseasepatients. Moreover, PTX3 has been suggested to represent a novel mortality risk factor, and elevated PTX3 levels have been shown to accompany increased albuminuria among patients with chronic kidney disease (CKD). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We analyzed data of 49 persons with stage 1 diabetic CKD and 32 healthy subjects in a prospective controlled trial. Endothelial dysfunction was determined by flow-mediated dilation (FMD). Serum PTX3, high-sensitivity C-reactive protein (hs-CRP) levels, and FMD were studied in baseline and after 12 wk of ramipril therapy. Stepwise multivariate regression analysis evaluated the association of FMD with clinical and serologic parameters. RESULTS: Serum PTX3, hsCRP, and albumin levels and proteinuria were significantly decreased, and FMD levels were significantly increased, after ramipril treatment. FMD was negatively correlated with serum PTX3, 24-h proteinuria, and hsCRP levels and positively correlated to serum albumin both at baseline and after the 12-wk treatment period. Multivariate regression analysis revealed that PTX3 levels were independently related to FMD both before and after ramipril treatment. CONCLUSIONS: Our study shows that serum PTX3 levels are associated with endothelial dysfunction in patients with stage 1 diabetic CKD, independent of CRP. In addition, short-term ACE-inhibitor treatment significantly improves FMD and normalizes PTX3, hsCRP, and urinary protein excretion. (NCT: The study was registered in clinicaltrials.gov as NCT00674596.).
Authors: Hans L Hillege; Vaclav Fidler; Gilles F H Diercks; Wiek H van Gilst; Dick de Zeeuw; Dirk J van Veldhuisen; Rijk O B Gans; Wilbert M T Janssen; Diederick E Grobbee; Paul E de Jong Journal: Circulation Date: 2002-10-01 Impact factor: 29.690
Authors: B Bottazzi; V Vouret-Craviari; A Bastone; L De Gioia; C Matteucci; G Peri; F Spreafico; M Pausa; C D'Ettorre; E Gianazza; A Tagliabue; M Salmona; F Tedesco; M Introna; A Mantovani Journal: J Biol Chem Date: 1997-12-26 Impact factor: 5.157
Authors: D S Celermajer; K Sorensen; M Ryalls; J Robinson; O Thomas; J V Leonard; J E Deanfield Journal: J Am Coll Cardiol Date: 1993-09 Impact factor: 24.094
Authors: Atul J Butte; Tara K Sigdel; Persis P Wadia; David B Miklos; Minnie M Sarwal Journal: Mol Cell Proteomics Date: 2010-12-23 Impact factor: 5.911
Authors: Mahmut Ilker Yilmaz; Juan Jesús Carrero; Jose Luis Martín-Ventura; Alper Sonmez; Mutlu Saglam; Turgay Celik; Halil Yaman; Mujdat Yenicesu; Tayfun Eyileten; Juan Antonio Moreno; Jesús Egido; Luis Miguel Blanco-Colio Journal: Clin J Am Soc Nephrol Date: 2010-04-29 Impact factor: 8.237
Authors: Tommaso Mauri; Giacomo Bellani; Nicolo' Patroniti; Andrea Coppadoro; Giuseppe Peri; Ivan Cuccovillo; Massimo Cugno; Gaetano Iapichino; Luciano Gattinoni; Antonio Pesenti; Alberto Mantovani Journal: Intensive Care Med Date: 2010-01-30 Impact factor: 17.440
Authors: Kultigin Turkmen; Fatih Mehmet Erdur; Ibrahim Guney; Huseyin Ozbiner; Aysun Toker; Abduzhappar Gaipov; Orhan Ozbek; Mehdi Yeksan; Halil Zeki Tonbul; Suleyman Turk Journal: Cardiorenal Med Date: 2012-11-16 Impact factor: 2.041